Abstract
Purpose
Lymphoma-associated haemophagocytic syndrome (LAHS) is a group of malignant diseases with rapid progression and a high mortality rate. Our study aimed to discover the significance of serum sCD25/ferritin ratio as well as cytokines in assisting the diagnosis of LAHS.
Methods
We retrospectively analyzed the clinical data of 82 patients with LAHS with hemophagocytic lymphohistiocytosis (HLH) as the first manifestation and divided them into B-LAHS group and T/NK-LAHS group according to lymphoma pathological diagnosis for comparison. And patients with LAHS were divided into responding group, non-responding group according to the assessment of efficacy after receiving DEP/L-DEP induction therapy for 2 weeks to compare possible valuable indicators.
Results
Serum sCD25/ferritin ratio and MCP-1 levels were significantly different between B-LAHS and T/NK-LAHS groups (P = 0.001, P = 0.022). An sCD25/ferritin ratio > 7.8 tended to suggest a diagnosis of B-LAHS (AUC = 0.71, 95% CI: 0.596–0.823), and the sCD25/ferritin ratio had better predictive value when combined with MCP-1 (AUC = 0.81, 95% CI: 0.699–0.922). The sCD25/ferritin ratio was also significantly different between the two groups responding or not responding to induction therapy (P = 0.002), yielding an optimal cutoff value of 11.48. An sCD25/ferritin ratio > 11.48 tended to suggest that the patient’s LAHS was responsive to induction therapy.
Conclusion
Our study reveals that serum sCD25/ferritin ratio combined with MCP-1 is a valid predictor for identifying LAHS with HLH as the first manifestation and may assist in predicting whether the lymphoma is of B-cell or T/NK-cell origin. The sCD25/ferritin ratio can also be used to predict the early response of LAHS after induction therapy.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Data availability
The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request.
References
Al-Samkari H, Berliner N (2018) Hemophagocytic lymphohistiocytosis. Annu Rev Pathol 13:27–49. https://doi.org/10.1146/annurev-pathol-020117-043625
Bains A, Mamone L, Aneja A, Bromberg M (2017) Lymphoid malignancy-associated hemophagocytic lymphohistiocytosis: search for the hidden source. Ann Diagn Pathol 28:37–42. https://doi.org/10.1016/j.anndiagpath.2017.02.009
Basavarajappa SC, Ramakrishnan P (2020) Regulation of B-cell function by NF-kappaB c-Rel in health and disease. Cell Mol Life Sci 77(17):3325–3340. https://doi.org/10.1007/s00018-020-03488-w
Boutilier AJ, Elsawa SF (2021) Macrophage polarization states in the tumor microenvironment. Int J Mol Sci 22(13):6995. https://doi.org/10.3390/ijms22136995
Chinese Physicians Association, Haematology Section, Chinese Medical Association, Haematology Group, Chinese Expert Alliance for Hemophagocytic Syndrome (2022) Chinese guidelines for the diagnosis and treatment of hemophagocytic syndrome (2022 edition). Chin Med J 102(20):1492–1499. https://doi.org/10.3760/cma.j.cn112137-20220310-00488
Cohen LA, Gutierrez L, Weiss A et al (2010) Serum ferritin is derived primarily from macrophages through a nonclassical secretory pathway. Blood 116(9):1574–1584. https://doi.org/10.1182/blood-2009-11-253815
El-Mallawany NK, Curry CV, Allen CE (2022) Haemophagocytic lymphohistiocytosis and Epstein–Barr virus: a complex relationship with diverse origins, expression and outcomes. Br J Haematol 196(1):31–44. https://doi.org/10.1111/bjh.17638
Fujiwara F, Hibi S, Imashuku S (1993) Hypercytokinemia in hemophagocytic syndrome. Am J Pediatr Hematol Oncol 15(1):92–98. https://doi.org/10.1097/00043426-199302000-00012
Henter JI, Horne A, Aricó M et al (2007) HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer 48(2):124–131. https://doi.org/10.1002/pbc.21039
Hua Z, He L, Zhang R, Liu M, Wang Z, Wang Y (2022) Serum ferritin is a good indicator for predicting the efficacy of adult HLH induction therapy. Ann Med 54(1):283–292. https://doi.org/10.1080/07853890.2022.2027513
Huang YH, Cai K, Xu PP et al (2021) CREBBP/EP300 mutations promoted tumor progression in diffuse large B-cell lymphoma through altering tumor-associated macrophage polarization via FBXW7-NOTCH-CCL2/CSF1 axis. Signal Transduct Target Ther 6(1):10. https://doi.org/10.1038/s41392-020-00437-8
Husson H, Carideo EG, Cardoso AA et al (2001) MCP-1 modulates chemotaxis by follicular lymphoma cells. Br J Haematol 115(3):554–562. https://doi.org/10.1046/j.1365-2141.2001.03145.x
Ishii E, Ohga S, Imashuku S et al (2007) Nationwide survey of hemophagocytic lymphohistiocytosis in Japan. Int J Hematol 86(1):58–65. https://doi.org/10.1532/IJH97.07012
Jordan MB, Allen CE, Greenberg J et al (2019) Challenges in the diagnosis of hemophagocytic lymphohistiocytosis: recommendations from the North American Consortium for Histiocytosis (NACHO). Pediatr Blood Cancer 66(11):e27929. https://doi.org/10.1002/pbc.27929
Kiessling MK, Klemke CD, Kaminski MM, Galani IE, Krammer PH, Gülow K (2009) Inhibition of constitutively activated nuclear factor-kappaB induces reactive oxygen species- and iron-dependent cell death in cutaneous T-cell lymphoma. Cancer Res 69(6):2365–2374. https://doi.org/10.1158/0008-5472.CAN-08-3221
Kim K, Ryu K, Ko Y, Park C (2005) Effects of nuclear factor-kappaB inhibitors and its implication on natural killer T-cell lymphoma cells. Br J Haematol 131(1):59–66. https://doi.org/10.1111/j.1365-2141.2005.05720.x
Klein U, Heise N (2015) Unexpected functions of nuclear factor-κB during germinal center B-cell development: implications for lymphomagenesis. Curr Opin Hematol 22(4):379–387. https://doi.org/10.1097/MOH.0000000000000160
Krei JM, Møller HJ, Larsen JB (2021) The role of interleukin-18 in the diagnosis and monitoring of hemophagocytic lymphohistiocytosis/macrophage activation syndrome—a systematic review. Clin Exp Immunol 203(2):174–182. https://doi.org/10.1111/cei.13543
La Rosée P, Horne A, Hines M et al (2019) Recommendations for the management of hemophagocytic lymphohistiocytosis in adults. Blood 133(23):2465–2477. https://doi.org/10.1182/blood.2018894618
Lehmberg K, Nichols KE, Henter JI et al (2015) Consensus recommendations for the diagnosis and management of hemophagocytic lymphohistiocytosis associated with malignancies. Haematologica 100(8):997–1004. https://doi.org/10.3324/haematol.2015.123562
Li W, Zhong Y, Shuang Y et al (2017) High concentration of miR-133 is a useful marker for the diagnosis of lymphoma-associated hemophagocytic syndrome. Cancer Biomark 20(2):159–164
Li N, Jiang M, Wu WC, Zhou HJ, Zou LQ (2022) Lymphoma-associated hemophagocytic syndrome: a retrospective study from a single center. Hematology 27(1):909–916. https://doi.org/10.1080/16078454.2022.2113600
Maruoka H, Inoue D, Takiuchi Y et al (2014) IP-10/CXCL10 and MIG/CXCL9 as novel markers for the diagnosis of lymphoma-associated hemophagocytic syndrome. Ann Hematol 93(3):393–401. https://doi.org/10.1007/s00277-013-1878-y
Otrock ZK, Hock KG, Riley SB, de Witte T, Eby CS, Scott MG (2017) Elevated serum ferritin is not specific for hemophagocytic lymphohistiocytosis. Ann Hematol 96(10):1667–1672. https://doi.org/10.1007/s00277-017-3072-0
Parikh SA, Kapoor P, Letendre L, Kumar S, Wolanskyj AP (2014) Prognostic factors and outcomes of adults with hemophagocytic lymphohistiocytosis. Mayo Clin Proc 89(4):484–492. https://doi.org/10.1016/j.mayocp.2013.12.012
Rubin LA, Nelson DL (1990) The soluble interleukin-2 receptor: biology, function, and clinical application. Ann Intern Med 113(8):619–627. https://doi.org/10.7326/0003-4819-113-8-619
Setiadi A, Zoref-Lorenz A, Lee CY, Jordan MB, Chen LYC (2022) Malignancy-associated haemophagocytic lymphohistiocytosis. Lancet Haematol 9(3):e217–e227. https://doi.org/10.1016/S2352-3026(21)00366-5
Shannon-Lowe C, Rickinson A (2019) The global landscape of EBV-associated tumors. Front Oncol 9:713. https://doi.org/10.3389/fonc.2019.00713
Swerdlow SH, Campo E, Harris NL (2017) WHO classification of tumours of haematopoietic and lymphoid tissues (revised 4th edn). Lyon, France
Tabata C, Tabata R (2012) Possible prediction of underlying lymphoma by high sIL-2R/ferritin ratio in hemophagocytic syndrome. Ann Hematol 91(1):63–71. https://doi.org/10.1007/s00277-011-1239-7
Tamura K, Kanazawa T, Tsukada S, Kobayashi T, Kawamura M, Morikawa A (2008) Increased serum monocyte chemoattractant protein-1, macrophage inflammatory protein-1beta, and interleukin-8 concentrations in hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer 51(5):662–668. https://doi.org/10.1002/pbc.21660
Tsuji T, Hirano T, Yamasaki H, Tsuji M, Tsuda H (2014) A high sIL-2R/ferritin ratio is a useful marker for the diagnosis of lymphoma-associated hemophagocytic syndrome. Ann Hematol 93(5):821–826. https://doi.org/10.1007/s00277-013-1925-8
Xie M, Li L, Zhu L et al (2018) An effective diagnostic index for lymphoma-associated hemophagocytic syndrome. QJM 111(8):541–547. https://doi.org/10.1093/qjmed/hcy103
Yao S, Jin Z, He L et al (2021) Clinical features and prognostic risk prediction of non-Hodgkin lymphoma-associated hemophagocytic syndrome. Front Oncol 11:788056. https://doi.org/10.3389/fonc.2021.788056
Yoshimura T (2017) The production of monocyte chemoattractant protein-1 (MCP-1)/CCL2 in tumor microenvironments. Cytokine 98:71–78. https://doi.org/10.1016/j.cyto.2017.02.001
Yoshimura T (2018) The chemokine MCP-1 (CCL2) in the host interaction with cancer: a foe or ally? Cell Mol Immunol 15(4):335–345. https://doi.org/10.1038/cmi.2017.135
Yu JT, Wang CY, Yang Y et al (2013) Lymphoma-associated hemophagocytic lymphohistiocytosis: experience in adults from a single institution. Ann Hematol 92(11):1529–1536. https://doi.org/10.1007/s00277-013-1784-3
Zhao A, Yang J, Li M et al (2022) Epstein–Barr virus-positive lymphoma-associated hemophagocytic syndrome: a retrospective, single-center study of 51 patients. Front Immunol 13:882589. https://doi.org/10.3389/fimmu.2022.882589
Zoref-Lorenz A, Murakami J, Hofstetter L et al (2022) An improved index for diagnosis and mortality prediction in malignancy-associated hemophagocytic lymphohistiocytosis. Blood 139(7):1098–1110. https://doi.org/10.1182/blood.2021012764
Funding
This work was supported by the National Natural Science Foundation of China [82170122].
Author information
Authors and Affiliations
Contributions
HZ, LH and YW contributed to the study conception and design. Material preparation, data collection and analysis were performed by all authors. The first draft of the manuscript was written by HZ and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.
Corresponding author
Ethics declarations
Conflict of interest
The authors have no relevant financial or non-financial interests to disclose.
Ethics approval
This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of Beijing Friendship Hospital (No. 2020-P2-096-01).
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Zou, H., He, L., Hue, Z. et al. Serum sCD25/ferritin ratio combined with MCP-1 is a valid predictor for identifying LAHS with HLH as the first manifestation. J Cancer Res Clin Oncol 149, 8521–8533 (2023). https://doi.org/10.1007/s00432-023-04781-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00432-023-04781-4